Epithelioid hemangioendothelioma presenting as fever of unknown origin

Natalia Vallianou¹, Aris Kollas¹, Nikos Schizas¹, Elina Theodorakopoulou¹, Elli Tripodaki¹, Christina Vourlakou¹, Ileanna Mani², Nikos Ziras²

¹Department of Internal Medicine, Evangelismos General Hospital, Athens, Greece ²Department of Oncology, Metaxa Oncology Hospital, Athens, Greece

Submitted: 8 April 2015 Accepted: 10 April 2015

Arch Med Sci 2017; 13, 3: 696–697 DOI: 10.5114/aoms.2016.64039 Copyright © 2016 Termedia & Banach

Epithelioid hemangioendothelioma (EHE) was first described by Weiss and Enzinger in 1982 and has been suggested to be a malignant vascular neoplasm with indolent behavior [1]. A 65-year-old female patient presented to our hospital with fever, back pain and pain in her buttocks. On examination, the only pathological sign were cutaneous nodules appearing in her right thigh (Figure 1 A). The histopathology of the nodule was compatible with epithelioid hemangioendothelioma (Figure 1 B). Positron emission tomography/computed tomography (PET/CT) scan revealed the presence of multiple lesions in various muscle groups as well as the invasion of bone marrow. The patient was referred to the oncology department, where she was treated for an angiosarcoma, with the combination of gemcitabine with docetaxel.

Epithelioid hemangioendothelioma is a vascular neoplasm of endothelial origin, which is considered to be intermediate between hemangioma and angiosarcoma [2]. It usually presents as a solitary, slightly painful papule, nodule or non-healing ulcer. Rarely, it may present as multiple lesions [3]. Epithelioid hemangioendothelioma is CD31, ERG, Fli-1 and factor WIII positive [4]. Occasionally, CD30 expression, although mainly associated with lymphoid malignancies and germ cell tumors, has also been reported in EHEs. This is important for the differential diagnosis, but it may also have therapeutic implications as CD30 positive patients could be candidates for targeted therapy based on the new CD30 antibody agents [5]. In most cases, a definite diagnosis of EHE remains challenging. Chromosomal translocation t(1;3)(p36;q25) is characteristic for EHE, and may serve as a diagnostic tool [1].

To our knowledge, this is the first report of EHE which presented as fever of unknown origin, due to its spread in the bone marrow, a fact that became prominent on PET/CT scan. Thus, this case also highlights the usefulness of PET/CT scan in the diagnostic algorithm of fever of unknown origin.

Conflict of interest

The authors declare no conflict of interest.

Corresponding author:

Natalia Vallianou Department of Internal Medicine Evangelismos General Hospital Polykliniki General Hospital 3 Pireaus St 105 52 Athens, Greece Phone: +3 2294092359 E-mail: natalia.vallianou@ hotmail.com






Figure 1. A – One of the cutaneous lesions that became visible and were compatible with epithelioid hemangioendothelioma. B – Hematoxylin and eosin 400×: Tumor consisted of a mixture of slightly pleomorphic spindle and epithelioid cells with abundant, sharply defined eosinophilic cytoplasm and vesicular nuclei containing single nucleoli

References

- 1. Mendlick MR, Nelson M, Pickering D, et al. Translocation t(1;3)(p36.3;q25) is a nonrandom aberration in epithelioid hemangioendothelioma. Am J Surg Pathol 2001; 25: 684-7.
- 2. Deyrup AT, Tighiouart M, Montag AG, Weiss SW. Epithelioid hemangioendothelioma of soft tissue: a proposal for risk stratification based on 49 cases. Am J Surg Pathol 2008; 32: 924-7.
- 3. Tanas MR, Sboner A, Oliveira AM, et al. Identification of disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med 2011; 3: 98ra82.
- 4. Park SY, Lee JK, Jo S, Huh CH, Cho KH, Ma JI. Cutaneous epithelioid hemangioendothelioma presented as an ulcerated areolar mass. J Dermatol 2013; 41: 112-3.
- Alimchandani M, Wang ZF, Miettinen. CD30 expression in malignant vascular tumors and its diagnostic and clinical implications: a study of 146 cases. Appl Immunohistochem Mol Morphol 2014; 22: 358-62.